Summary
Forty-eight patients with advanced breast cancer were treated in a disease-specific phase I trial of doxorubicin and iproplatin combination chemotherapy. The doses of doxorubicin ranged between 30 and 50 mg/m2, and the doses of iproplatin ranged between 150 and 250 mg/m2. Myelosuppression was observed at all levels, but was dose-limiting at the highest level. In addition, nausea, diarrhea and malaise were prominent toxicities. Neither cardiac nor renal toxicity was encountered. Nine of 26 (35%) of previously untreated patients, and 5 of 22 (23%) previously treated patients demonstrated partial or complete responses. Although this combination possesses therapeutic activity, given its toxicities, further evaluation of doxorubicin in combination with iproplatin is not recommended.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoogstraten B, Fabian C: A reappraisal of single drugs in advanced breast cancer. Cancer Clin Trials 2:101–109, 1979
Bull JM, Tormey DC, Li SH: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41:1649–1657, 1978
Tormey DC, Weinberg VE, Leone LA, Glidewell OJ, Perloff M, Kennedy BJ, Cortes E, Silver RT, Weiss RB, Aisner J, Holland JF: A comparison of intermittent vs. continuous and of adriamycin vs. methotrexate 5-drug-chemotherapy for advanced breast cancer. Am J Clin Oncol 7:231–239, 1984
Sledge Jr GW, Loehrer Sr PJ, Roth BJ, Einhorn LH: Cisplatin as first-line therapy for metastatic breast cancer. (Abstr) Proc Amer Soc Clin Oncol 6:53, 1987
Kolaric K, Roth A: Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer. Cancer Chemother Pharmacol 11:108–112, 1983
Forastiere AA, Hakes TB, Wittes JT, Wittes RE: Cisplatin in the treatment of metastatic breast cancer. Am J Clin Oncol (CCT) 5:243–247, 1982
Ginsberg SJ: CHIP. Phase I study. SUNY Upstate Medical Center. Minutes of the phase II meeting; December 12, 1983; Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland
Atassi G, Kenis Y, Dumont P, Rozencweig M: Animal screening of new platinum derivatives — studies with single agents and combinations. Proc 4th NCI-EORTC symposium on new drugs in cancer therapy. Brussels 1983
Miller AB, Hoogstraten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981
Breast Cancer Task Force, Treatment Commitee, National Cancer Institute: Breast Cancer: Suggested Protocol Guidelines for Combined Modality Trials. Washington DC, United States Department of Health Education and Welfare, Publication No (NIH) 77-1192
Meisner D, Ginsberg S, Nicaise C, Ditch A, Louie A, Newman N, Comis R, Poiesz B: A phase II trial of iproplatin (CHIP) in previously treated breast cancer. (Abstr) Proc Amer Soc Clin Oncol 6:63, 1987
Sierocki JS, Hilaris BS, Hopfan S, Martini N, Barton D, Golbey RB, Wittes RE: cis-Dichlorodiammineplatinum (II) and VP-16–213: an active induction regimen for small cell carcinoma of the lung. Cancer Treat Rep 63:1593–1597, 1979
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Casper, E.S., Curley, T. & Hakes, T.B. Phase I clinical trial of doxorubicin and iproplatin combination chemotherapy in patients with breast cancer. Invest New Drugs 7, 189–193 (1989). https://doi.org/10.1007/BF00170856
Issue Date:
DOI: https://doi.org/10.1007/BF00170856